Ultrafiltration bei kardiorenalem Syndrom

ZUSAMMENFASSUNG

Das kardiorenale Syndrom (KRS) umfasst heterogene Erkrankungen von Herz und Niere, die im Wesentlichen durch eine wechselseitige Funktionsstörung von Herz und Nieren gekennzeichnet sind. Das häufig führende Symptom ist die Überwässerung, für die therapeutisch neben der klassischen diuretischen Behandlung auch interventionelle Verfahren zur Verfügung stehen. Die konservativen Therapiemöglichkeiten geraten gerade bei eingeschränkter Nierenfunktion oftmals an ihre Grenzen – trotz neuerer Kombinationstherapien zur Steigerung der diuretischen Effektivität mit SGLT2-Inhibitoren (SGLT2: „sodium glucose linked transporter 2“) oder Carboanhydrasehemmern. Interventionelle Verfahren kommen bei therapierefraktärer Herzinsuffizienz daher entweder zur isolierten Ultrafiltration bei alleiniger Volumenüberladung oder zur Nierenersatztherapie mittels Hämo- oder Peritonealdialyse zum Einsatz. Bei letzterer ist die Peritonealdialyse als besonders vorteilhaft hervorzuheben aufgrund der kontinuierlichen Ultrafiltration mit einer höheren hämodynamischen Stabilität, positiven kardialen Effekten und einer hohen Patientenautonomie.

Publication History

Article published online:
31 May 2023

• Literatur

• 1 House AA, Wanner C, Sarnak MJ. et al Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95: 1304-1317
• 2 Heywood JT, Fonarow GC, Costanzo MR. et al High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422-430
• 3 Logeart D, Tabet JY, Hittinger L. et al Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008; 127: 228-232
• 4 Gheorghiade M, Zannad F, Sopko G. et al Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958-3968
• 5 Ponikowski P, Voors AA, Anker SD. et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975
• 6 Wertman BM, Gura V, Schwarz ER. Ultrafiltration for the management of acute decompensated heart failure. J Card Fail 2008; 14: 754-759
• 7 Peacock WF, Costanzo MR, De Marco T. et al Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009; 113: 12-19
• 8 Felker GM, Lee KL, Bull DA. et al Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805
• 9 Hasselblad V, Gattis Stough W, Shah MR. et al Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 09: 1064-1069
• 10 ter Maaten JM, Valente MA, Damman K. et al Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol 2015; 12: 184-192
• 11 McDonagh TA, Metra M, Adamo M. et al 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
• 12 Mullens W, Dauw J, Martens P. et al Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022; 387: 1185-1195
• 13 Schulze PC, Bogoviku J, Westphal J. et al Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 2022; 146: 289-298
• 14 Konstam MA, Gheorghiade M, Burnett Jr JC. et al Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331
• 15 Kitsios GD, Mascari P, Ettunsi R. et al Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J Crit Care 2014; 29: 253-259
• 16 Kazory A, Sgarabotto L, Ronco C.. Extracorporeal ultrafiltration for acute heart failure. Cardiorenal Med. 2022
• 17 Wilcox CS, Testani JM, Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension 2020; 76: 1045-1054
• 18 Francis GS, Siegel RM, Goldsmith SR. et al Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985; 103: 1-6
• 19 Cadnapaphornchai MA, Gurevich AK, Weinberger HD. et al Pathophysiology of sodium and water retention in heart failure. Cardiology 2001; 96: 122-131
• 20 Kim G-H. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004; 24: 595-605
• 21 Schwenger V, Remppis BA, Westenfeld R. et al Dialyse- und Ultrafiltrationsverfahren bei kardio-renalem Syndrom. Empfehlung der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. und der Deutschen Gesellschaft für Nephrologie e. V. Dtsch Med Wochenschr 2014; 139: e1-e8
• 22 Patschan D, Drubel K, Matyukhin I. et al Kidney replacement therapy in cardiorenal syndromes. J Clin Med Res 2022; 14: 264-272
• 23 Leskovar B, Furlan T, Poznič S. et al Hemodialysis treatment of cardiorenal syndrome. Clin Nephrol 2017; 88: 57-60
• 24 Premuzic V, Basic-Jukic N, Jelakovic B. et al Continuous veno-venous hemofiltration improves survival of patients with congestive heart failure and cardiorenal syndrome compared to slow continuous ultrafiltration. Ther Apher Dial 2017; 21: 279-286
• 25 Fiaccadori E, Regolisti G, Maggiore U. et al Ultrafiltration in heart failure. Am Heart J 2011; 161: 439-449
• 26 Bart BA, Boyle A, Bank AJ. et al Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005; 46: 2043-2046
• 27 Bart BA, Goldsmith SR, Lee KL. et al Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304
• 28 Costanzo MR, Guglin ME, Saltzberg MT. et al Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-683
• 29 Costanzo MR, Negoianu D, Jaski BE. et al Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC Heart Fail 2016; 04: 95-105
• 30 Marenzi G, Muratori M, Cosentino ER. et al Continuous ultrafiltration for congestive heart failure: the CUORE trial. J Card Fail 2014; 20: 9-17
• 31 Wańkowicz Z, Próchnicka A, Olszowska A. et al Extracorporeal versus peritoneal ultrafiltration in diuretic-resistant congestive heart failure--a review. Med Sci Monit 2011; 17: RA271-RA281
• 32 Globe Newswire. CHF Solutions expands commercial presence in Europe with distribution arrangement for Germany, Austria and Switzerland (12.02.2020). Im Internet. https://www.wallstreet-online.de/nachricht/12162463-chf-solutions-expands-commercial-presence-europe-with-distribution-arrangement-for-germany-austria-and-switzerland (31.01.2023)
• 33 CHF Solutions, Inc. Annual report on form 10-K (31.12.2018). Im Internet. https://www.sec.gov/Archives/edgar/data/1506492/000114036119003638/s002681x1_10k.htm (31.01.2023)
• 34 Kazory A, Bargman JM. Defining the role of peritoneal dialysis in management of congestive heart failure. Expert Rev Cardiovasc Ther 2019; 17: 533-543
• 35 Bertoli SV, Musetti C, Ciurlino D. et al Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int 2014; 34: 64-70
• 36 Courivaud C, Kazory A, Crepin T. et al Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int 2014; 34: 100-108
• 37 Grossekettler L, Schmack B, Meyer K. et al Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail 2019; 06: 271-279
• 38 Pavo N, Yarragudi R, Puttinger H. et al Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction. PLoS One 2018; 13: e0206830
• 39 Al-Hwiesh AK, Abdul-Rahman IS, Al-Audah N. et al Tidal peritoneal dialysis versus ultrafiltration in type 1 cardiorenal syndrome: a prospective randomized study. Int J Artif Organs 2019; 42: 684-694
• 40 Rao VS, Turner JM, Griffin M. et al First-in-human experience with peritoneal direct sodium removal using a zero-sodium solution: a new candidate therapy for volume overload. Circulation 2020; 141: 1043-1053
• 41 Wojtaszek E, Grzejszczak A, Niemczyk S. et al Peritoneal ultrafiltration in the long-term treatment of chronic heart failure refractory to pharmacological therapy. Front Physiol 2019; 10: 310
• 42 Caplin NJ, Zhdanova O, Tandon M. et al Acute peritoneal dialysis during the COVID-19 pandemic at Bellevue Hospital in New York City. Kidney360 2020; 01: 1345-1352